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To determine the biological and clinical relevance of programmed death 1 (PD-1) in follicular lymphoma (FL), we characterized PD-1 + T-cell subsets and assessed their biological function as well as potential clinical impact. We found that PD-1 is expressed on intratumoral CD4 + T cells with both bright and dim intensity, representing two different sub-populations of cells. By immunohistochemistry, we found that CD4
+ PD-1 high T cells predominantly reside in the lymph node follicles, while PD-1 low T cells are mainly located in an interfollicular pattern. Intratumoral CD4 + PD-1 high T cells have a T FH cell phenotype, express CXCR5, secrete IL-21 and are BCL-6 positive with no TIM-3 expression. In contrast, CD4
+ PD-1 low T cells have an exhausted phenotype, express TIM-3 and do not express BCL-6 and CXCR5. Functionally, CD4 + PD-1 high T cells actively supported B-cell growth, while CD4 + PD-1 low T cells displayed a reduced cytokine production and cell-signal transduction. Clinically, we observed that the numbers of CD4 + or CD8 + PD-1 low T cells significantly correlate with a reduced overall survival in FL patients (P = 0.007 and 0.04 respectively; n = 32). In contrast, the number of CD4 + PD-1 high T cells was not associated with patient outcome. Taken together, these results indicated that PD-1 expression defines two sub-populations with distinct functions that differentially impact patient outcome in FL. 1,2 Previous studies have shown that the type of T-cell-mediated immune response determines the anti-tumor immunity [3] [4] [5] thereby impacting patient outcome. [6] [7] [8] In FL, lymph node follicles remain intact, while the germinal centers become larger due to increasing numbers of lymphoma B cells. Similar to normal lymph nodes, T cells reside both outside and inside the follicles. These intratumoral T cells are generally heterogenous and influence tumor immunity both positively and negatively, depending on the prevalence of various T-cell populations and location of the cells. For example, while high numbers of tumor-infiltrating Foxp3 + cells are associated with an improved overall survival in FL, 8 patients with Foxp3 + cells located in a follicular pattern (intrafollicular or perifollicular) had a significantly elevated risk of transformation and shorter survival than patients with Foxp3
+ cells present in a diffuse pattern. Programmed death 1 (PD-1), a member of the CD28/CTLA-4 family, has been shown to negatively regulate T-cell receptor signaling and decrease proliferation and cytokine production in T cells. The involvement of regulatory T cells (T reg ) in the interaction of PD-1 and PD-L1 contributes to PD-1-mediated inhibition of T cells. Recently, PD-1 has been demonstrated to be a major component in the process of T-cell exhaustion, 10, 11 although complex mechanisms are involved in inducing exhaustion. It has been shown that TIM-3, a family member of T-cell immunoglobulin and mucin domain proteins, along with other molecules, are co-expressed with PD-1 on exhausted T cells. 12, 13 In contrast however, PD-1 is also expressed on T cells present within the follicles of secondary lymphoid organs, and this subset of T cells has been identified as follicular helper T (T FH ) cells. [14] [15] [16] Because of the unique location, T FH cells are able to closely interact with B cells to promote the formation of germinal centers and to help B cells produce long-lived memory B cells and highaffinity antibodies.
In a previous work, we observed that PD-1 was expressed by different subsets of intratumoral T cells in FL including T FH cells and exhausted T effector cells. 17, 18 However, the function, prevalence, distribution and clinical importance of the respective intratumoral PD-1 + T subsets in FL patients are largely unknown. In this study, we determined the expression of PD-1 and identified the location and intensity of PD-1 staining in the tumor tissue of FL by immunohistochemistry and flow cytometry. We measured the biological function of different subsets of PD-1 + T cells and clinical impact in FL patients.
MATERIALS AND METHODS

Patient samples
Patients providing written informed consent were eligible for this study if they had a tissue biopsy that on pathologic review showed follicular B-cell non-Hodgkin's lymphoma and adequate tissue or peripheral blood to perform the experiments. Peripheral blood mononuclear cells from healthy donors and lymph nodes from patients with hyperplasia were used as controls. The use of human tissue samples for this study was approved by the Institutional Review Board of the Mayo Clinic/Mayo Foundation.
Cell isolation and purification
Fresh tumor biopsy specimens from patients with FL and normal lymph nodes were gently minced over a wire mesh screen to obtain a cell suspension. The cell suspension or peripheral blood from patients or healthy donors was centrifuged over Ficoll Hypaque at 500 g for 15 
Statistical analysis
Statistical analysis was performed by using Student's t test. Significance was determined at Po0.05. Overall survival was measured from the date of diagnosis until death from any cause. Patients alive and still at risk of death at last follow-up evaluation were censored for the analysis of overall survival. Survival of all patients was estimated by using the Kaplan-Meier method. The univariate association between PD-1 expression and survival was determined with the log-rank test.
RESULTS PD-1 is expressed in the tumor microenvironment of FL It has been shown that signaling through PD-1 has a critical role in T-cell-mediated immune responses in a variety of pathophysiological conditions. To determine the role of PD-1 in FL, we first measured its expression in biopsy lymph nodes of FL patients. By immunohistochemistry, we observed that PD-1 was highly expressed in FL biopsy specimens ( Figure 1a) . By flow cytometry, we found that PD-1 was abundantly expressed on intratumoral CD3 + T cells while CD19 + B cells and CD14 + monocytes had a negligible expression of PD-1 on cell surface ( Figure 1b) .
Next, we determined PD-1 expression on intratumoral CD4 + and CD8 + T cells in FL. We saw a different pattern of PD-1 expression between the CD4 + and CD8 + subset. For CD4 + T cells, we could distinguish CD4 + T cells as two populations based on PD-1 expression (Figure 1c ). Some CD4 + T cells had PD-1 expressed at high levels (PD-1 high ), while other cells expressed a low level of PD-1 (PD-1 low ). For CD8 + T cells, the PD-1 high population was not seen and only the PD-1 low population existed (Figure 1c ). Supporting this finding, we observed that PD-1 stained brightly in cells mostly within the follicles (Figure 1d ). However, at high power, cells that stained dimly for PD-1 were seen in the interfollicular region (Figure 1d ). (Figure 4b) . Next, to topographically identify PD-1 low and TIM-3 + cells in FL tissue, we stained tissue sections for PD-1 and TIM-3. We again saw bright staining for PD-1 on cells in the follicles, while weak staining for PD-1 could be seen between follicles. Similar to the PD-1 low expression pattern, TIM-3 was expressed on cells between the follicles, suggesting a co-expression pattern between PD-1 low and TIM-3 on cells in interfollicular regions (Figure 4c ). Because co-expression of PD-1 and TIM-3 suggested a possible exhausted phenotype, we further tested for additional markers of T-cell activation and exhaustion. As shown in Figure 4d To functionally characterize PD-1 low TIM-3 + T cells, we first measured cytokine production by this subset using cells from FL specimens. An intracellular staining assay was employed to measure the cytokine production of PD-1 low TIM-3 + T cells stimulated with phorbol myristate acetate/ionomycin in the presence of Brefeldin A for 4 h. As shown in Figure 5a , the vast majority of IL-2-or IFN-γ-producing cells came from TIM-3 − T cells. T cells in the tumor microenvironment has an impact on patient outcomes in FL. To do this, we evaluated a cohort of 32 previously untreated FL patients who had diagnostic biopsy specimens available for analysis and who had been followed for long-term outcome (Table 1 ). All patients subsequently received chemotherapy in combination with rituximab as therapy for the disease although many patients were initially observed. We first measured the numbers of PD-1 + , PD-1 high CXCR5 + or PD-1 low TIM-3 + T cells in both CD4 and CD8 population of biopsy specimens from this cohort of patients. On average, the numbers of PD + cells accounted for 53.13% ± 18.57% (range: 17.22-92.57%, n = 32) and 46.82% ± 14.71% (range: 12.78-81.73%, n = 32) of CD4 + and CD8 + T cells in LNs of FL patients, respectively (Figure 6a ). Among CD4 + PD-1 + T cells, the numbers of PD-1 high CXCR5 + or PD-1 low TIM-3 + T cells were similar and accounted for 26.60% ± 15.82% and 26.39% ± 9.76% of CD4 + T cells in LNs of FL patients, respectively. Among CD8 + PD-1 + T cells, however, the numbers of PD-1 high CXCR5 + were very low (4.83% ± 7.91%) and PD-1 low TIM-3 + (42.08% ± 11.88%) accounted for the most of CD8 + PD-1 + T cells (Figure 6a ).
Given that PD-1 expression levels separated CD4 + T cells into 2 subsets with distinct phenotype and function, we predicted that these two subsets would have a different role in impacting patient outcomes. We therefore correlated the numbers of CD4 + PD-1 high or CD4 + PD-1 low T cells with patient survival. As shown in Figure 6b , using 26% as a cutoff point (the mean number of PD-1 + CD4 + T cells), we found that the numbers of CD4 + PD-1 low T cells were associated with a poorer survival in this FL patient cohort (Figure 6b) . Similarly, the frequency of CD8 + PD-1 low T cells also significantly correlated with an inferior outcome in this cohort of PD-1 expression in follicular lymphoma Z-Z Yang et al patients (Figure 6b ). In contrast, we found that the frequency of CD4 + PD-1 high T cells did not correlated with outcome in FL patients (Figure 6c ).
DISCUSSION
The significant finding in the present study is that PD-1 expression levels divide intratumoral T cells into subsets with different phenotype and function that differentially impact outcome of FL patients. These findings may explain why the contribution of intratumoral PD-1 + T cells to patient outcome in FL has been controversial. Although some studies have found that increased numbers of PD-1 + T cells correlate with an inferior prognosis 19 or have no impact on patient outcome, 20 other studies observed that the numbers of intratumoral PD-1 + T cells are an indicator of a favorable outcome in FL. 21 The different PD-1 + cell populations we show to be present in FL may explain the differences in the findings of these studies. Because immunohistochemistry was the major method to count PD-1 positive-staining cells in tissue slides in these studies, this method may count different populations of cells. In the present study, we show that two distinct populations of cells express PD-1 and the prevalence of these subsets may impact patient outcome.
PD-1, a member of the CD28/CTLA-4 family, has been shown to negatively regulate T-cell receptor signaling and decrease proliferation and cytokine production in T cells. However, recent studies demonstrated that PD-1 expression is involved in different functions in T-cell subsets depending on the location where the cells reside. For example, PD-1-expressing T cells located in the follicles are T FH cells that exhibit help function to B cells, which is different from the cells originally described. Our results are in agreement with this finding and we found that a subset of T cells located within follicles that express high levels of PD-1 as well as CXCR5. Similar to previous reports, these CD4 + PD-1 high cells express Bcl-6 22 and secret IL-21, 23 two molecules specifically expressed by T FH cells.
In addition to its expression on T FH cells, recent findings have shown that PD-1 can be upregulated in exhausted T cells. We therefore addressed the question as to which characteristics separate PD-1 + T FH from PD-1 + -exhausted T cells. We used FL as a model as both populations are present in FL lymph nodes, and found that PD-1 expression level and location as well as co-expression of CXCR5 or TIM-3 distinguish T FH from exhausted T cells. In FL, T FH cells express high levels of PD-1, reside in intrafollicular regions and co-express CXCR5. In contrast, exhausted T cells express low levels of PD-1, reside in interfollicular regions and co-express TIM-3. CD8 + T cells only have a PD-1 low population, in which TIM-3 is co-expressed, suggesting an exhausted phenotype. In a previous report, however, it was found that the PD-1 high population contained both T FH and non-T FH T cells and some cells displayed functional changes similar to exhausted T cells including a reduced cytokine signaling. 25 In our study, we did not find that PD + PD-1 low T cells expressed TIM-3 and displayed a reduced cytokine production with a little signal transduction in response to cytokine stimulation. These findings are in agreement with the previous reports that PD-1 + TIM-3 + T cells are exhausted and have reduced the capacity to proliferate and produce cytokines. 17, 26 Further supporting these findings, we found that PD-1 low T cells, especially PD-1 low CD8 + subset, constitutively expressed high level of 2B4, a marker of late stage exhaustion, and lacked expression of OX40, a co-stimulatory molecule.
Clinically, we found that the numbers of both CD4 + and CD8 + PD-1 low T cells significantly correlated with a poor prognosis in FL patients, which is in line with a previous report that the frequency of intratumoral CD4 + TIM-3 + T cells predicts an inferior survival in FL patients. In contrast, the numbers of CD4 + PD-1 high were not associated with survival in FL patients. Supporting this finding, we observed that patients with transformation had increased PD-1 low and decreased PD-1 high T cells in FL. These results indicate that PD-1 plays a role not only in T-cell-mediated tumor immunity, but also in tumor cell biology in FL.
In conclusion, we have defined two distinct T-cell sub-populations based on PD-1 expression levels. 
